Connor, Clark & Lunn Investment Management (CC&L)
GBT

Connor, Clark & Lunn Investment Management (CC&L)’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-61,589
Closed -$1.97M – 1288
2022
Q2 		$1.97M Buy
61,589
+54,486
+767% +$1.59M 0.01% 474
2022
Q1 		$246K Sell
7,103
-12,796
-64% -$383K ﹤0.01% 913
2021
Q4 		$582K Sell
19,899
-108,780
-85% -$3.37M ﹤0.01% 773
2021
Q3 		$3.28M Buy
+128,679
New +$3.78M 0.02% 424

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s GBT Position: Q3 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 61,589 shares — an estimated $1.97M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in GBT in Q3 2021 and held it in 4 quarters. The position peaked at $3.28M in Q3 2021. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 61,589 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $1.97M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Global Blood Therapeutics, Inc. in Q3 2021 and held it in 4 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Global Blood Therapeutics, Inc. position peaked at $3.28M in Q3 2021.
  • 247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2022, filed 10 Nov 2022.